Email this article 
Aliskiren in Patients Failing to Achieve Blood Pressure Targets With Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers
Abstract
Background: To assess the efficacy of aliskiren in patients failing to reach blood pressure (BP) goals with angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB).
Methods: A total of 107 patients who failed to reach BP goals on ACEI or ARB were switched to aliskiren. Changes in BP were determined during maximal ACEI, ARB, or aliskiren therapy.
Results: Mean reduction in sBP and dBP with ACEI was 8.5 6.3 mmHg and 6.0 4.7 mmHg, respectively. Mean reduction in sBP and dBP with ARB was 8.3 6.7 mmHg and 5.0 5.2 mmHg, respectively. Mean reduction in sBP and dBP with aliskiren 150 mg/d was 6.7 5.4 mmHg and 5.4 4.8 mmHg, respectively. Mean reduction in sBP and dBP with aliskiren 300 mg/d was 8.6 6.3 mmHg and 6.0 4.9 mmHg, respectively. BP reductions between ACEI, ARB, and aliskiren were not significantly different.
Conclusions: Aliskiren is ineffective in patients failing ACEI or ARB therapy. Given the label changes restricting the use of aliskiren in combination with ACEI and ARB, excess cost compared to ACEI and ARB, and a paucity of outcome data, there is a limited role for aliskiren in practice.
Cardiol Res. 2012;3(4):147-153
doi: https://doi.org/10.4021/cr201w
Methods: A total of 107 patients who failed to reach BP goals on ACEI or ARB were switched to aliskiren. Changes in BP were determined during maximal ACEI, ARB, or aliskiren therapy.
Results: Mean reduction in sBP and dBP with ACEI was 8.5 6.3 mmHg and 6.0 4.7 mmHg, respectively. Mean reduction in sBP and dBP with ARB was 8.3 6.7 mmHg and 5.0 5.2 mmHg, respectively. Mean reduction in sBP and dBP with aliskiren 150 mg/d was 6.7 5.4 mmHg and 5.4 4.8 mmHg, respectively. Mean reduction in sBP and dBP with aliskiren 300 mg/d was 8.6 6.3 mmHg and 6.0 4.9 mmHg, respectively. BP reductions between ACEI, ARB, and aliskiren were not significantly different.
Conclusions: Aliskiren is ineffective in patients failing ACEI or ARB therapy. Given the label changes restricting the use of aliskiren in combination with ACEI and ARB, excess cost compared to ACEI and ARB, and a paucity of outcome data, there is a limited role for aliskiren in practice.
Cardiol Res. 2012;3(4):147-153
doi: https://doi.org/10.4021/cr201w
Keywords
Aliskiren; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Hypertension